Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Florence Myrick

Showing results (61-70 of 69) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 69 results.
Medical Teacher|June 28, 2007
The anatomy and physiology of conflict in medical education: a doorway to diagnosing the health of medical education systemsRussell J Sawa, Anne Phelan, Florence Myrick, et al.
Antiviral Research|May 12, 2005
Effects of HIV Q151M-associated multi-drug resistance mutations on the activities of (-)-beta-D-1',3'-dioxolan guanineJoy Y Feng, Florence Myrick, Boulbaba Selmi, et al.
Antiviral Therapy|June 9, 2006
In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabineKatyna Borroto-Esoda, Jennifer E Vela, Florence Myrick, et al.
Retrovirology|May 15, 2009
The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action studyJoy Y Feng, John K Ly, Florence Myrick, et al.
Antiviral Therapy|May 28, 2005
Lack of a metabolic and antiviral drug interaction between tenofovir, abacavir and lamivudineAdrian S Ray, Florence Myrick, Jennifer E Vela, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 11, 2008
The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutationEvguenia S Svarovskaia, Joy Y Feng, Nicolas A Margot, et al.
Hepatology (Baltimore, Md.)|March 5, 2011
No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virusAndrea Snow-Lampart, Brandi Chappell, Maria Curtis, et al.
Antimicrobial Agents and Chemotherapy|December 7, 2007
Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131Tomas Cihlar, Adrian S Ray, Constantine G Boojamra, et al.
Alberta RN|April 3, 2010
Call for individual actionWendy Austin, Nancy Barnes, Vera Caine, et al.
Pageof 7

Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
Medical Teacher|June 28, 2007
The anatomy and physiology of conflict in medical education: a doorway to diagnosing the health of medical education systemsRussell J Sawa, Anne Phelan, Florence Myrick, et al.
Antiviral Research|May 12, 2005
Effects of HIV Q151M-associated multi-drug resistance mutations on the activities of (-)-beta-D-1',3'-dioxolan guanineJoy Y Feng, Florence Myrick, Boulbaba Selmi, et al.
Antiviral Therapy|June 9, 2006
In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabineKatyna Borroto-Esoda, Jennifer E Vela, Florence Myrick, et al.
Retrovirology|May 15, 2009
The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action studyJoy Y Feng, John K Ly, Florence Myrick, et al.
Antiviral Therapy|May 28, 2005
Lack of a metabolic and antiviral drug interaction between tenofovir, abacavir and lamivudineAdrian S Ray, Florence Myrick, Jennifer E Vela, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 11, 2008
The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutationEvguenia S Svarovskaia, Joy Y Feng, Nicolas A Margot, et al.
Hepatology (Baltimore, Md.)|March 5, 2011
No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virusAndrea Snow-Lampart, Brandi Chappell, Maria Curtis, et al.
Antimicrobial Agents and Chemotherapy|December 7, 2007
Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131Tomas Cihlar, Adrian S Ray, Constantine G Boojamra, et al.
Alberta RN|April 3, 2010
Call for individual actionWendy Austin, Nancy Barnes, Vera Caine, et al.
Pageof 7